Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDF5 (growth differentiation factor 5) is a member of the bone morphogenetic protein (BMP) family and the TGF-beta superfamily, encoded by the human GDF5 gene. It functions as a **cytokine** critical for cartilage and bone formation, joint development, and neuronal growth. As a dimeric protein, it binds with high affinity to type I and type II BMP receptors—most specifically BMPR1B and BMPR2—activating the SMAD signaling pathway and promoting downstream transcriptional responses. GDF5 selectively regulates neuronal dendrite growth via SMAD-dependent upregulation of transcription factors such as HES5. It is expressed physiologically in skeletal tissues and the developing central nervous system, increasing survival of dopamine-responsive neurons, and is being studied for therapeutic use in conditions like intervertebral disc degeneration (IDD), osteoarthritis (OA), Parkinson's disease, and bone/cartilage regeneration. Mutations in GDF5 are linked to skeletal dysplasias and joint disorders[1][2][3][5][6][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gdf5.